Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer

Annals of Oncology

Volumn 7, Issue 2, 1996, Pages 129-133

  Binder, C ^a   Marx, D ^a   Binder, L ^a   Schauer, A ^a   Hiddemann, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Bax; Bcl 2; Breast cancer; Prognostic factors

Indexed keywords

HORMONE RECEPTOR; ONCOPROTEIN; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029939051     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010538     Document Type: Article

References (33)

1. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 1993; 74: 609-19.
2. Boise LH, Gonzalez-Garcia M, Postema CE et al. Bcl-X, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
3. 1 and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-91.
4. Kozopas KM, Yang T, Buchan HL et al. mcll, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to bcl2. Proc Natl Acad Sci USA 1993; 90: 3516-20.
5. Chittenden T, Harrington EA, O'Connor R et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995; 374: 733-6.
6. Yin X-M, Oltvai Z, Korsmeyer S. Heterodimerization with Bax is required for Bcl-2 to repress cell death. Curr Top Microbiol Immunol 1995; 194: 331-8.
7. Zhang H, Saeed B, Ng S-H. Combinatorial interaction of human Bcl-2 related proteins: Mapping of regions important for Bcl-2/Bcl-x-s interaction. Biochem Biophys Res Comm 1995; 208: 950-6.
8. Sedlak T, Oltvai Z, Yang E et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-8.
9. Joenssu H. Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term-survival in breast cancer. Am J Pathol 1994; 145: 1191-8.
10. Doglioni C, DeiTos AP, Laurino L et al. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994; 424: 47-51.
11. Leek RD, Kaklamanis L, Pezzella F et al. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor-receptor-negative tumors and in situ cancer. Br J Cancer 1994; 69: 135-9.
12. Nathan B, Gusterson B, Jadayel D et al. Expression of Bcl-2 in primary breast cancer and its correlation with tumor phenotype. Ann Oncol 1994; 5: 409-14.
13. Silvestrini R, Veneroni S, Daidone MG et al. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86:499-504.
14. Binder C, Marx D, Overhoff R et al. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 1995; 6: 1005-10.
15. Hellemans P, van Dam PA, Weyler J et al. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995; 72:354-60.
16. Sierra A, Lloveras B, Castellsagué X et al. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995; 60: 54-60.
17. Gee J, Robertson J, Ellis I et al. Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994, 59: 619-28.
18. Johnston, SR, MacLennan KA, Sacks NP et al. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 1994; 30A: 1663-9.
19. Krajewski S, Krajewska M, Shabaik A et al. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323-36.
20. Barghou R, Daniel P, Mapara M et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-α expression in tumor cells correlates with resistance to apoptosis. Int J Cancer 1995;60:854-9.
21. Bloom HJG, Richardson WW. Histologic grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
22. Meden H, Marx D, Raab T et al. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: Immunohistochemical findings and prognostic value. J Obstet Gynaecol 1995; 21: 167-78.
23. Marx D, Schauer A, Reiche C et al. C-erbB-2-expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 1990; 116: 15-20.
24. Krajewski S, Blomquist C, Franssila K et al. Reduced expression of proapoptotic gene box is associated with poor response rates to combination therapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-8.
25. Teixeira C, Reed J, Pratt C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 protooncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-7.
26. Miyashita T, Harigai M, Hanada M et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-5.
27. Miyashita T, Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell 1995; 80: 293-9.
28. Haldar S, Negrini M, Monne M et al. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-7.
29. Liang XH, Mungal S, Ayscue A et al. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995; 5: 509-21.
30. Krajewski S, Krajewska M, Shabaik A et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994; 54; 5501-7.
31. Chao D, Linette G, Boise L et al. Bcl-xL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995; 182: 821-8.
32. Benito A, Grillot D, Nunez G et al. Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am J Pathol 1995; 146: 481-90.
33. Pietenpol JA, Papadopoulos N, Markowitz S et al. Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer Res 1994; 54: 3714-7.